



The Cataylst Initiative: Innovative CME on Appropriate Use of Immunotherapy in the Systemic Treatment of Locally Advanced and Metastatic BCC and cSCC




aging System
Definition
Tumor <2 cm in g
Tumor ≥2 cm, bu
Tumor ≥4 cm in g erosion or perine
Tumor with gross
Tumor with skull foramen involver
sion: ≥0.1 mm or nerve l beyond subcutaneous fa an Joint Committee on Ca MB et al, editors. AJCC Cancer

Over Time, Learners Have Shown Progress in Applying



Conclusions



mechanisms and the latest immunotherapy data, both oncologists and dermatologists need more education on identifying BCC and cSCC patients who would benefit from immunotherapy. Future education to focus on individual patient scenarios.



animation-based, micro-learning opportunities, as well as tools for use in the practice setting.



claims of learners pre- and post- education will offer insight into application of knowledge gains in regards to appropriate use of the latest clinical data.

FC21 Poster, Med Learning Group, CME supported by educational grants from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

a control group to assess behavior change over

Fall Clinical **Dermatology Conference** October 21 - 24, 2021

